Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes

Download All
Get up to date on optimal use of BTK inhibitors in the care of your patients with CLL with an interactive on-demand Webcast and downloadable slides from a live Webinar, along with expert commentaries and our BTK Inhibitor AE Management Tool.
Ian W. Flinn, MD, PhD
Program Director
Ian W. Flinn, MD, PhD
Susan M. O'Brien, MD
John Pagel Headshot
John Pagel, MD, PhD
Farrukh T. Awan, MD
Christopher R. Flowers, MD, MS
Nicole Lamanna, MD
John P. Leonard, MD
Julie M. Vose, MD, MBA

ClinicalThought

In this commentary, Ian W. Flinn, MD, PhD, provides expert answers to frequently asked questions on the use of BTK inhibitors in the management of patients with CLL.

Ian W. Flinn, MD, PhD Released: November 16, 2020

In this commentary, experts answered clinician questions on first-line treatment of CLL, including the use of targeted therapies and FCR, the risk of COVID-19 infection with different regimens, and management of autoimmune manifestations.

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to see strategies to assess and manage adverse events associated with BTK inhibitors from 5 experts in managing patients with hematologic malignancies.


Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 4, 2020

Downloadable Slidesets

Download this slideset from Ian Flinn, MD, PhD to review the rational and overview of the data on the use of BTK inhibitors for patients with CLL.

Ian W. Flinn, MD, PhD Released: December 4, 2020

Download this slideset from Ian W. Flinn, MD, PhD and Susan M. O’Brien, MD for the most recent data selecting first-line therapy for patients with CLL, including differences in treatment selection for patients with or without del(17p) or TP53 mutations.

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD Released: December 4, 2020

Download this slideset from John Pagel, MD, PhD for the most up-to-date data on therapy for patients with R/R CLL, including novel approaches that may impact clinical practice in the near future.

John Pagel Headshot John Pagel, MD, PhD Released: December 4, 2020

Download this short summary slideset of key takeaways from a live CCO Webinar focused on key data for using BTK inhibitors in patients with CLL.

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: December 9, 2020

On-Demand Webcast

Watch this on-demand Webcast capturing a live CCO Webinar to learn more about the latest data on BTK inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with CLL.

Ian W. Flinn, MD, PhD
Program Director
Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: December 8, 2020 Expired: December 7, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue